Tolerability, pharmacokinetics and pharmacodynamics of PF-4236921 administered as single ascending intravenous and subcutaneous doses in volunteers

Trial Profile

Tolerability, pharmacokinetics and pharmacodynamics of PF-4236921 administered as single ascending intravenous and subcutaneous doses in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2012

At a glance

  • Drugs PF 4236921 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 01 Jul 2012 New trial record
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top